Dose-Response Relationship, Drug

"Dose-Response Relationship, Drug" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The relationship between the dose of an administered drug and the response of the organism to the drug.

Descriptor ID	D004305
MeSH Number(s)	G07.690.773.875 G07.690.936.500
Concept/Terms	Dose-Response Relationship, Drug Dose-Response Relationship, Drug Dose-Response Relationships, Drug Drug Dose-Response Relationship Drug Dose-Response Relationships Relationship, Drug Dose-Response Relationships, Drug Dose-Response Dose Response Relationship, Drug

Below are MeSH descriptors whose meaning is more general than "Dose-Response Relationship, Drug".

Biological Sciences [G]
Physiological Phenomena [G07]
Pharmacological and Toxicological Phenomena [G07.690]
Pharmacological Phenomena [G07.690.773]
Dose-Response Relationship, Drug [G07.690.773.875]
Toxicological Phenomena [G07.690.936]
Dose-Response Relationship, Drug [G07.690.936.500]

Below are MeSH descriptors whose meaning is related to "Dose-Response Relationship, Drug".

Below are MeSH descriptors whose meaning is more specific than "Dose-Response Relationship, Drug".

Dose-Response Relationship, Drug
Hormesis
Lethal Dose 50

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Dose-Response Relationship, Drug" by people in this website by year, and whether "Dose-Response Relationship, Drug" was a major or minor topic of these publications.

Bar chart showing 733 publications over 30 distinct years, with a maximum of 50 publications in 2005

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	12	12
1997	0	8	8
1998	0	17	17
1999	0	13	13
2000	0	12	12
2001	0	15	15
2002	0	32	32
2003	0	36	36
2004	0	32	32
2005	0	50	50
2006	1	41	42
2007	0	39	39
2008	1	41	42
2009	0	38	38
2010	0	39	39
2011	0	36	36
2012	0	30	30
2013	0	28	28
2014	0	30	30
2015	0	30	30
2016	1	34	35
2017	1	21	22
2018	0	23	23
2019	0	21	21
2020	0	15	15
2021	0	11	11
2022	0	1	1
2024	1	6	7
2025	0	15	15
2026	0	2	2

Below are the most recent publications written about "Dose-Response Relationship, Drug" by people in Profiles.

Holden DN, Dingman JS, Sutton LH, Ramos-Estebanez C, El Ammar F, Warinpramote J, Siddiqui R, Choi R, Schneider L, Baker R, Bonderski V, Morsi RZ, Desai H, Kass-Hout T, Singh J, Kuhn AL, Puri AS, Gutierrez-Aguirre SF, Hanel RA, Zaidat OO, Ashouri Y, AlMajali M, Anderson E, Wetmore L, Barats M, Kimmons L, Scott W, Webb A, Johnson R, O'Donnell JN, Entezami P. Multicenter evaluation of the safety and efficacy of varying doses of cangrelor used in acute cerebrovascular stenting in patients with acute ischemic stroke. J Neurointerv Surg. 2026 Apr 16; 18(5):1372-1377.

View in: PubMed
Johnson ML, Patel MR, Falchook GS, Koyama T, Gutierrez M, Awad MM, Piha-Paul SA, Friedman CF, Satoh T, Okamoto N, Singh J, Yoshizuka N, Windish HP, Qian M, Tran BP, Doi T. Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial. Lancet Oncol. 2026 Apr; 27(4):491-501.

View in: PubMed
Kaur J, Spielvogel E, Nageswara Rao D, Rusere LN, Shaqra AM, Lockbaum GJ, Maryam A, Yilmaz NK, Swanstrom R, Schiffer CA, Ali A. Fluorinated HIV-1 protease inhibitors containing chiral hydroxyethylbenzene and indanol as P2' ligands with potent activity against drug-resistant variants. Eur J Med Chem. 2026 Feb 15; 304:118510.

View in: PubMed
D'Almeida RE, Chen P, Huang Y, Goetz E, Sammeta VR, Yang B, Rao RP, Rasapalli S, Elfawal MA. Design, synthesis, and biological evaluation of a focused pyrrolo- and pyrido-quinazolinone natural products-templated library for anti-fungal and anthelmintic activities. Bioorg Med Chem. 2026 Mar; 134:118517.

View in: PubMed
Gao Y, Du C, Xu Y, Cheng X, Zhao H, Jiang F, Cheng N, Xiang Y, Zhang Y, Li Y, Liu H, Chai X, Lian X, Zhao W, Li N. Optimal Levothyroxine Dosing Strategy for Immune Checkpoint Inhibitor-related Hypothyroidism: A Retrospective Study. J Clin Endocrinol Metab. 2025 Nov 18; 110(12):3342-3353.

View in: PubMed
Singh A, Barasa L, DeOrsey L, O'Reilly MD, Choudhary S, Cahill SE, Rossetti T, Green RM, Humphries F, Thompson PR. Triazole-based STING inhibitors. Bioorg Med Chem. 2026 Jan 01; 132:118484.

View in: PubMed
Hill AD, Teja B, Burry L, Pinto R, Bosch NA, Walkey A, Stelfox HT, Chapman M, Scales DC, Wunsch H. Variation in Maximal Doses of Vasopressors Used for Treatment of Shock in Intensive Care Units in Alberta Canada: A Retrospective Cohort Study. Anesth Analg. 2026 06 01; 142(6):1088-1097.

View in: PubMed
Saberi S, Abraham TP, Choudhury L, Barriales-Villa R, Elliott PM, Nassif ME, Oreziak A, Owens AT, Tower-Rader A, Rader F, Garcia-Pavia P, Olivotto I, Coats CJ, Fifer MA, Sherrid MV, Solomon SD, Watkins H, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Melloni C, Meng L, Wei J, Maron MS, Masri A. Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM. JACC Heart Fail. 2025 Aug; 13(8):102496.

View in: PubMed
Maher TM, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M, Oldham JM, Richeldi L, Valenzuela C, Wijsenbeek MS, Clerisme-Beaty E, Coeck C, Gu H, Ritter I, Schlosser A, Stowasser S, Voss F, Weimann G, Zoz DF, Martinez FJ. Nerandomilast in Patients with Progressive Pulmonary Fibrosis. N Engl J Med. 2025 Jun 12; 392(22):2203-2214.

View in: PubMed
Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ, Oldham JM, Valenzuela C, Clerisme-Beaty E, Gordat M, Wachtlin D, Liu Y, Schlecker C, Stowasser S, Zoz DF, Wijsenbeek MS. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2025 Jun 12; 392(22):2193-2202.

View in: PubMed

People

Explore

Similar Concepts

Top Journals